Podcast appearances and mentions of sam hellman

Sam Hellman, CFB writer from 247Sports joins K&K to evaluate the college football season at the quarter pole for the 2022 season. Plus, the guys compare their projected brackets set by future 12-team playoff rules.See omnystudio.com/listener for privacy information.

On this edition of Klahr & Kompany, Michael kicks things off right away with "Broncos Blast" pt. 1 featuring Ian St. Clair from MIleHighReport, who joins Michael to discuss if this game vs the 49ers will in fact be the game the Broncos get back on track on offense. Plus, will Russell Wilson's experience against San Francisco be the ultimate factor? The guys debate.. Next is "Kickin' It With Kiz" featuring award-winning sports writer for the Denver Post, Mark Kiszla, who joins Michael to rank the highest paid "franchise" players in Denver- Russell Wilson ($245mil), Nikola Jokic ($270mil), Nathan MacKinnon ($100.8mil) and [questionably] Kris Bryant ($182mil). Who deserves the top spot? The fellas discuss.. Batting third is Sam Hellman, CFB writer from 247Sports who joins K&K to evaluate the college football season at the quarter pole for the 2022 season. Plus, the guys compare their projected brackets set by future 12-team playoff rules. Batting cleanup and rounding out hour 1 is "In the Slot" featuring Evan Rawal from DNVR Avalanche who joins the show to talk the beginning of the title defense as they return to training camp. Plus, the guys discuss MacKinnon's new deal and can this team perform well again in front of suspect goal-tending?See omnystudio.com/listener for privacy information.

Adapt or Perish is back, and with Episode 118, we're taking an extended look at the adventure classic The Three Musketeers! We've also got a new focus for the show, and we can't wait for you to see what we've got planned! In this episode, we discuss: Alexandre Dumas' original 1844 novel The Three Musketeers, the 1921 movie, directed by Fred Nibble, written by Edward Knoblock, Douglas Fairbanks, and Lotta Woods, and starring Fairbanks, Léon Bary, George Siegmann, and Eugene Pallette The Three Musketeers, the 1935 movie, directed by Rowland V. Lee, written by Lee and Dudley Nichols, and starring Walter Abel, Paul Lukas, Moroni Olsen, and Onslow Stevens The Three Musketeers, the 1939 movie musical, directed by Alan Dwan, written by William A. Drake, M.M. Musselman, Sam Hellman, Ray Golden, and Sid Kuller, and starring Don Ameche and the Ritz Brothers The Three Musketeers, the 1948 movie, directed by George Sidney, written by Robert Ardrey, and starring Gene Kelly, Lana Turner, June Allyson, Vincent Price, and Van Heflin The Three Musketeers, the 1966 series, directed by Peter Hammond, written by Anthony Steven, and starring Jeremy Brett, Brian Blessed, Jeremy Young, Gary Watson, and Richard Pasco The Three Musketeers and The Four Musketeers, the 1973 and 1974 movies, directed by Richard Lester, written by George MacDonald Fraser, and starring Michael York, Oliver Reed, Frank Finlay, Richard Chamberlain, Charlton Heston, Faye Dunaway, Raquel Welch, and Christopher Lee The Three Musketeers, the 1993 movie, directed by Stephen Herek, written by David Loughery, and starring Chris O'Donnell, Charlie Sheen, Kiefer Sutherland, Oliver Platt, and Tim Curry The Musketeer, the 2001 movie, directed by Peter Hyams, written by Gene Quintano, and starring Justin Chambers, Tim Roth, Mena Suvari, Jean-Pierre Castaldi, Stephen Rea, and Catherine Deneuve The Three Musketeers, the 2011 movie, directed by Paul W.S. Anderson, written by Anderson and Andrew Davies, and starring Logan German, Matthew Macfadyen, Ray Stevenson, Luke Evans, Mads Mikkelsen, and Milla Jovovich The Musketeers, the 2014–2016 series, created by Adrian Hodges, and starring Tom Burke, Santiago Cabrera, Howard Charles, and Luke Pasqualino Footnotes: History Tea Time with Lindsay Holiday "Voila" from The Three Musketeers (1939), but seriously, watch the whole thing, it's a delight Frock Flicks "All For Love" performed by Bryan Adams, Rod Stewart, and Sting You can follow Adapt or Perish on Twitter, Instagram, and Facebook, and you can find us and all of our show notes online at adaptorperishcast.com. We're also on Patreon! You can find us at patreon.com/adaptcast. We have multiple reward levels, which include access to a patron-only community and a patron-only, biweekly bonus show! We hope to see you there. If you want to send us a question or comment, you can always email us at adaptorperishcast@gmail.com.

On this edition of Klahr & Kompany, Michael will look into the free-agent frenzy for Joe Sakic and the Avs, and which names we'll see tyr and to back-to-back. Plus, the ever shifting landscape in college football. Michael is first joined by Jim Armstrong and top-10 sports writer in the country, Mark Kiszla from the Denver Post, the guys discuss where Joe Sakic and the Avs will go in free agency which opens up in a few days. Goaltender Darcy Kuemper is already moving on, but will Nichushkin or Kadri be the next to stay? The fellas discuss.. Next is Sam Hellman, from 247Sports, joins Michael to talk about the shifting NCAA landscape and how it can possibly become a regional sport. Plus, where will CU and the Pac-12 end up when a seismic type shift stops? Rounding out hour 1 is Sean Deveney from Forbes Sports & Heavy.com joins Michael to discuss the NBA power shifts after free agency. Plus, their reaction to some of these Nuggets' rookies in their first summer league action!See omnystudio.com/listener for privacy information.

#RadOnc legend Dr. Ralph Weichselbaum joins The Accelerators (Drs. Anna Laucis, Simul Parikh, and Matt Spraker) for one of our favorite episodes ever. We kick off by discussing how to #MedTwitter, the state of technology and proton therapy, and radiation resource allocation. Then we discuss Ralph and Sam Hellman's 1995 paper, Oligometastases, the history of the concept, and where we are headed. This leads to a scientific discussion on the abscopal effect.We close the show with an epic new segment: the lightning round! We grill Ralph on pizza, the MD/PhD degree, the best cities for conferences, and why #RadOnc would benefit from broadening our scope of work to include delivery of select systemic therapies.Here are some other things that came up on the show:Michigan Radiation Oncology Quality Consortium Ralph and Sam Hellman's (2011) Oligometastases revisitedTurchan, Pitroda, and Weichselbaum (2021) on radiotherapy and immunotherapy for patients with metastatic disease. Pitroda and colleagues (2018) on molecular subtyping to define an oligometastatic state in colorectal cancer. Tsai and colleagues trial (2021) of SBRT for oligometastases from non-small cell lung cancer and breast cancer.Robin Mole's (1953) original description of the abscopal effect.Postow and colleagues (2012) NEJM case report of the abscopal effect. Sylvia Formenti's Nature Medicine (2018) paper on radiotherapy plus immune check point inhibitors. Huang and colleagues Nature (2017) paper on T-cell invigoration.McNeil, Weichselbaum, and Parker NEJM study (1981) on trade-offs between quality and quantity of life.See also: McNeil, Weichselbaum, and Parker (1978) on the Fallacy of the Five-Year Survival in Lung Cancer.Podcast art generously donated by Dr. Danielle Cunningham.

Michael hosted the show solo and opened the show reacting to the Broncos' schedule. Michael also previewed the Nuggets heading into the playoffs. Jim Armstrong and Mark Kiszla joined the show to preview the Avalanche in the Stanley Cup Playoffs. Sam Hellman called in to give his thoughts on college football so far this year. Ted Trackman Johnson joined the show and previewed this weekend's Preakness race.  See omnystudio.com/listener for privacy information.

Hour two of Klahr and Kompany, Michael Klahr with Mark Knudson talked with Sam Hellman about the current landscape of college football and how that will translate to the playoffs. Bruce Marshall gave his weekly picks and Adam Munsterteiger concluded previewing the CU Buffs first 2020 football game against UCLA and who the Buffs starting quarterback will be to start the season.  See omnystudio.com/listener for privacy information.

Dr. Hayes interviews Dr. Lichter on his involvement with early breast preservation.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Welcome to JCO's Cancer Stories-- the Art of Oncology, brought to you by the ASCO podcast network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the role of cancer care. You can find all of the shows, including this one, at podcast.asco.org. Today, my guest on the podcast is Dr. Allen Lichter Dr. Lichter has a long and really storied history in the field of oncology over the last five decades. With his colleagues at the NCI, Drs. David Danforth and Mark Lippman, he was the radiation oncologist PI for one of the four studies that demonstrated that breast preserving therapy was as effective as mastectomy for newly diagnosed breast cancer. He more or less single-handedly started the Department of Radiation Oncology at the University of Michigan, now considered one of the top programs in the world. He is one of only three radiation oncologists to have been a dean at a major university in the United States, serving as such at the University of Michigan Medical School for eight years. And he is one of only three radiation oncologists who have been president of ASCO. The others are Sam Hellman, who I've interviewed previously, and our current president, Dr. Lori Pierce, who, by the way, is also from the University of Michigan. And his term was from 1997 to 1999. Dr. Lichter was born and raised in the Detroit area. He received his undergraduate and his medical degrees at the University of Michigan, after which he completed an internship at a community hospital-- St. Joseph's in Denver-- and then a residency in radiation oncology at the University of California, San Francisco. Following that, he joined the faculty at Johns Hopkins University, but after two short years there, he moved a few miles south to the National Cancer Institute in 1978, where he was head of the radiation therapy section of the radiation oncology branch. I believe you couldn't have been more than 32 or 33 years old, Allen, at the time. I counted up the years. He then moved back to Michigan to start the department here, which he chaired for eight years, and then became the dean for eight years. And then he went on to become the Chief Executive Officer of ASCO from 2006 to 2016. In spite of spending the last 20 years of his career as an administrator, Dr. Lichter has authored over 120 peer-reviewed papers. He was the co-editor of Clinical Oncology, one of the major textbooks on oncology, and has really been a leader, especially in radiation oncology, but in cancer in general in this country. I also want to add he was my boss for eight years when I first moved to University of Michigan, and during which time he was also my next door neighbor here in Ann Arbor. And I got to be his boss for one year-- if anybody could be Allen Lichter's boss-- from my term as ASCO president. Dr. Lichter, welcome to our program. It's great to be here, Dan. So a number of questions. I know, first of all, you grew up in Detroit and you went to Cass High School. And while this podcast is supposed to be about the history of oncology, having moved to Ann Arbor, I find the history of Cass High School awfully interesting. Has a number of famous alums, including Diana Ross, Lily Tomlin, Ellen Burstyn, Della Reese, David Alan Grier, Jack White, Alice Coltrane, and-- my guess is, Allen, you don't even know who Big Sean is, but he's a rapper. He's very famous right now for the younger generation. Any memories from your time there? Did you run into celebrities when you were there? It's quite a place to say you're from, I think. It's an interesting school, mostly a technical high school, located in downtown Detroit, but with a small college preparatory program that took students from all over the city with a competitive entrance exam. And I don't know what possessed me to get on the Second Avenue bus and ride downtown back and forth every day, but it was a fascinating experience. It takes you out of your normal peer group. I met young people-- friends-- from all walks of life, from all corners of the city. And it was a pretty rigorous education. I enjoyed it a great deal. And I played on the golf team. And it sounds to me like you knew you'd be a doctor then. Your father was a family practice doc in a small community just outside of Detroit. Was that true? Did you plan to go to medical school? Or did you have some epiphany when you were at high school? No, I never remember a single day not wanting to be a physician. My dad was a general practitioner and really instilled in my brother, and in me, a love of science and a love of medicine. My brother went on to be an ophthalmologist and was chair of the department at the University of Michigan for 34 years, President of the American Academy of Ophthalmology. So my dad and my brother set great examples for me, and into medicine I went. So I have to tell you, my father was a business man and was disappointed that I was in academics because he never understood why I wasn't generating income. My brother went to work for Eli Lilly. He was a doctor, too. And dad always thought he was doing something productive because he worked for Eli Lilly. So I don't know if your dad was disappointed you went to academics instead of family practice, but-- It was interesting. When I started my residency training, I was certainly confident that I would head into private practice and live a life much like my father did. And when I finished training, I decided I just needed a little more buffing up. I figured I'd go into academics for a couple of years, just to make sure I had a good grounding, and then go into private practice. I love the academic life and stayed there my whole career. I've been fond of asking previous interviewees-- why'd you choose oncology, and specifically radiation oncology, in your case? What led you to go into this path? Especially 40 years ago-- there wasn't a whole lot of oncology to go into. Well, you know, I was one of those medical students that loved virtually every rotation, and after that rotation I was going to become a fill in the blank. In my senior year of medical school, we were allowed to take an away elective, and I wanted to explore radiology as a potential field. My brother had a very good friend who was a radiation oncologist at the University of California, San Francisco, and the chance in the early 70s to go to San Francisco-- especially avoiding the Michigan winter-- was very compelling. So I signed up for the electives, and when I got there, I found that it was six weeks of diagnostic radiology and six weeks of radiation oncology. I hadn't expected that, but what the heck. So I did my six weeks of down in the basement looking at teaching sets, which was really quite inspirational. And I went into radiation oncology. And after my first day, I called my father and I said, I found what I'm going to do. I'm going into radiation oncology. It was instantly fascinating. I love the camaraderie in the department. I love the blend between the physical exams of patients, the treatment of cancer, the use of very high technology equipment and physics. It just struck me and I never wavered from that point on. So I've heard you talk about this-- and I'm 10 years behind you and even was true when I trained-- was that there wasn't a whole lot of science in radiation oncology back 40 years ago. And the field has evolved. And there are two things-- one you already hit on, which is it was combined with diagnostic radiology. And the second is it split away from diagnostic radiology to become its own field, and a lot of science. I've spoken with Saul Rosenberg and Sam Hellman and sort of asked them the same question. Give us just a background of the last 40 years of the evolution of radiation oncology because you had a lot to do with that. Well, of course, the field grew up, as you point out, inside the broad field of radiology. I always would tell my trainees that when Rankin discovered the X-ray, he forgot to discover the instruction manual. So there was a trial and error learning with this very useful technology, but very dangerous technology over a long period of time. For quite some period of time, you trained in general radiology. You had some time in diagnostic a little time in therapy, and you went out and could do both. But as I entered the field, it was becoming more and more difficult to learn radiation oncology in just the few weeks that they rotated in from their diagnostic duties. And I was one of the earliest group of trainees who trained in straight radiation oncology-- no diagnostic training, per se. And the field, as you say, split from diagnostic radiology. Had our own boards. I was amongst the earliest group to take the specialty board in radiation oncology. And the other thing that was true, certainly back in the late 60s and early 70s, is that so much of the field was experiential-- that is, people wrote papers like, you know, the last 100 patients with cancer of the lung that I treated. And this was valuable, but the need to do rigorous, well-controlled clinical trials was obvious to everyone inside the field. And so the field did become much more scientific. Never quite much as medical oncology, and part of that is because devices are treated differently at the FDA than drugs. Drugs you have to prove through scientific investigation that the agent is safe and effective. And then you can release it for patient use. For devices, you just have to prove that it basically doesn't kill anybody. And you can get an approval of a device and often get a billing code for the device. So the approval comes, and then you're supposed to do the science. Well, a lot of people, at that point, they're just too busy using the technology, then, to actually step back and do the science. And, of course, if you spent a lot of money for a piece of technology, to do the science to find out that wasn't a very wise investment is not in your self-interest. So our science lagged behind. I think it is certainly catching up, but it's still, in fact, in many cases, has a ways to go. I have enormous respect for our colleagues in the FDA on the devices side, and their hands are tied a bit. But I liken some of what they do to being like underwriter's laboratory. If you plug it in, it doesn't blow up, so they approve it. Yes. It's a little more than that, but you're right. And so much of the device approvals are based on a predicate of a similar device. And it goes from A to B to C and finally, you know, years down the road, the equipment and its use and its underlying structure is so different from the original device that was approved years ago that you rely on, at every step of the way, it really has-- there's been a lot of scrutiny about changing that, and I think over time it will change. You know, historically, it's interesting, by what you just said-- some of the first prospective randomized trials in all of medicine were radiation versus nil to the chest wall with breast cancer. To my knowledge, streptomycin versus nil for tuberculosis was the first, but then a whole series of radiation versus nil. But who would you give credit in the United States-- I would give part credit to you with the work you did with Drs. Lippman and Danforth. Probably one of the first randomized trials in radiation in this country. Well, you're correct that the first chest wall radiation trial started in Manchester, England in 1948. And at that point, doing randomized trials-- giving some patients the therapy and other patients observing or giving them a placebo-- that was not in widespread use in medicine. And over time, those types of trials began to become more common. I think in radiation oncology, our big advance was becoming part of the national co-operative group system, where many of the co-operative groups-- maybe all of them-- had a radiation oncology committee. And our studies were often integrated with surgical care or combined modality care with chemotherapy. And so we began a series of very important studies in breast cancer and lung cancer. The pediatric group did many, many trials that involved plus or minus radiation. I don't know that there's any specific person I'd give credit to, but it was the movement inside the field to join our other oncology colleagues in testing things rather than just doing observational work. You know, in that regard, let's circle back to your work at the NCI. That must've taken a fair amount of organizational and political skills to mount a breast preserving therapy, just at the NCI. The data that breast preserving therapy was safe was just beginning to be reported. The randomized trials in other places were ongoing. Give us some story there, how the three of you got that going and how you ran that. Well, of course, virtually everything at the NCI, from a clinical standpoint, is a clinical trial. Patients aren't treated there, just as going to their community hospital. You come to the NCI-- the travel is paid for, the care is paid for, et cetera, based on your agreement to enter into a study. At the time that I went to the NCI, the NSABP was doing their very large trial of lumpectomy versus mastectomy under Bernie Fisher's direction. My concerns were twofold. Number one-- this was being done at many, many centers around the country, and one could, I think, logically ask the question whether the quality of that care was going to be uniformly high enough to truly test breast preservation therapy. And secondly, I believed-- and many of us believed at the time-- that a boost to the tumor bed was quite important as part of having a low rate of local recurrence, and the NSABP study did not use the boost. They just treated the whole breast and stopped. And I said, you know, let's do a trial where it's done at a single institution, where the quality is going to be absolutely top notch, where we're going to use a boost and all of the technical tricks that we knew how to do this, just in case the NSABP study didn't come through. We'd have a backup. If both of them were negative, we could forget about lumpectomy and radiation, but if the NSABP was negative, we'd have this. As it turned out, the NSABP study, as you know, was positive, established for sure the equivalence of preservation therapy, and our study was sort of a little caboose at the end of the train. But that's OK. It confirmed what Ernie and colleagues confirmed very emphatically. Actually, there's an interesting article in the JCO written by Ian [INAUDIBLE] and his colleagues, about six months ago, that he preluded when he won the award your last year as CEO at ASCO. Was it your award? I can't remember. Yes. But anyway-- yeah. And in which, he designated the term I hadn't heard before of statistical fragility. And he made the point that many single prospective randomized trials are positive and the subsequent ones are not. And I give you and, of course, the Italians and the Brits also ran similar trials. It's nice to have four trials that all show the same thing. There's no statistical fragility in this observation. Yes, well, the NSABP trial was 1,800 patients. Our trial was about 240. We weren't going to change the world, but it was at least comforting to me that we had this trial coming along just in case. The other academic success that I give you credit for and would love to hear more about it is that you're interested in CT planning, which I think, really, was the forerunner, now, of stereotactic radiation and I would call precision radiation, as opposed to just blasting an organ and hoping you hit the cancer. And I think, really, a lot of that you brought when you started the department here. But how did you get interested in that? When I went to the NCI, my first day there, they took me on a tour of the department and we walked by a room with a locked door. I said, what's in there? And they said, oh that's our CT scanner, but we never use it. So I said, well, let me see it. And, you know, this was an EMI 5005. This was one of the early scanners. It was a body scanner, but it had a fairly small aperture. You could not get a lot of Americans into this machine. And I said, well, why don't we start scanning some patients. As long as-- does anybody know how to use this thing? Yes? OK, let's start scanning some patients. And it didn't take long to recognize that this was a machine that was almost tailor made to do radiation therapy planning. It gave you the contour of the patient's surface. It showed you the inside of the patient. It showed you the tumor in most settings. And remember, at that time we were facing radiotherapy treatment planning on plain x-rays taken on the simulator where, for example, when you treated the prostate, you never saw the prostate. You knew where the pubis was. You knew where the rectum was. You knew where the bladder was. And you knew the prostate had to be in there somewhere, but you never saw it. When we started to CT scan the pelvis in prostate cancer patients, there was the prostate in all its anatomic glory. And so we began to plan on this. And then it became pretty clear that if you took these slices and stacked them back up, like if you took a loaf of bread and it was laying out on the table as individual slices and stacked the slices back up, you could rebuild the three dimensional picture of the loaf. We decided that that might be a good thing to do with CT scans. And that's when I went to Michigan, and that's when we brought together some terrific physicists and brilliant programmers and spent a lot of money on a roomful of computers and began to do three dimensional reconstruction. And that led to a transformation in radiation therapy from a two dimensional specialty to a three dimensional specialty. And you could start firing at the tumor from cross sections from different directions. We didn't have to be in the actual plane, et cetera, et cetera, et cetera. And then we put a multi-leaf on the aperture, and so you could shape the field in real time. And it just went from there. So I have to tell you, when I was a first year fellow at Sidney Farber Cancer Institute, and I saw a patient who had received chest wall radiation-- not at our institution, by the way, not even in Massachusetts. She'd come from one of the other states. And basically, they had just stood her up in front of the machine and turned it on, as far as I could see. And the amount of normal tissue damage that she had suffered from this was incredible. And I called your friend, Jay Harris, and said, is this what we do here? He said, no way. Had me come down-- he showed me the beginnings of their CT planning and that sort of thing. I didn't know [INAUDIBLE] at the time, but then I learned later, mostly because of your doing. There were a number of outstanding institutions that were involved in this, and a lot of the inspiration for this came from some of the work that Sam Hellman was writing about, in terms of how we might better use imaging. So it was a team effort across the whole specialty. By the way, you bring up Dr. Hellman. We just lost Eli Glatstein in the last few months. I'll give you an opportunity to say some nice things about him. I know that you worked with him, and he was a giant in the field. The reason I was attracted down to the NCI is that this little short pudgy guy, Eli Glatstein, was recruited from Stanford by Vince Devita to come and run the radiation oncology branch. It was a pretty interesting time. There were five of us with Eli. All five of us became department chairs after our time at the NCI. He was just a phenomenal individual. He gave you a lot of rope. You could either hang yourself, or you could do the work you wanted to do. And we accomplished a lot. The other thing that I remember-- so I went to the NCI 1978. 1980, Eli said to me-- he handed me a piece of paper. I said, what's this? He says, it's an application form to join ASCO. You need to join ASCO. So I said, OK. That's not typically what radiation oncologists do, but I'll join. He sponsored me. And then he said, I'm going to see if I can't get you on a committee. And he did. I was on early Grants Award Committee. We handed out five or six young investigator grants. And I became chair of that committee. And then they said, well, you know, you did a nice job. We're going to put you on another committee, and way led to way. It was entirely because of Eli that I got introduced to ASCO and became such an important part of my life. He was a giant and will be sorely missed by all of us. And that's a perfect segue into my last question, which is changing gears completely, and that is your career at ASCO. Give us some ideas of what ASCO was like in the late 70s and how it has evolved-- principally, I mean, I know that's a whole hour long discussion, but I think you've had such a huge footprint in the society-- and what you saw changed, and the important changes. You know, ASCO was founded in 1964. There were no oncologists in 1964. There were doctors who were treating cancer-- some of them with surgery, some of them with radiation, some of them with these very early, highly toxic drugs. And so the society was formed. And it specifically says, when you read the early writings about this by the founders, that this was not a society of what they called chemotherapeutists. It was a society of physicians who wanted to treat cancer. They brought together all of the clinical specialties. I like to joke that the most interesting thing is that the medical oncologists forgot to found the American Society of Medical Oncology. They're the only specialty in medicine that doesn't have a specifically focused society just for them. They used ASCO, and to this day, it remains that way. And so I got involved. And the leaders of ASCO in the 70s and 80s and into the 90s, espousing how wonderful their multidisciplinary work was. And they used to have annual member meetings at the ASCO annual meeting. And the board would sit up on the dais, and the peanut gallery would ask questions. So I raised my hand, and I walked to the microphone, and I said, you know, it's great how you extol the multidisciplinary nature of the society. But I look at the dais, and I see the 12 members of the board of ASCO, and they're all medical oncologists. You are not practicing what you preach. And I sat down, and they mumbled a few things. And then the next thing I knew, darn it, they created board slots for a surgeon, a radiation oncologist, and a pediatric oncologist. And then they said, all right, big mouth, now that you held our feet to the fire, we're going to run you for the board. And I did get elected to the board, and then, eventually, got elected president. And then when they needed a CEO in 2006, they asked me if I was interested, and I interviewed for the job and then moved to Washington and then Alexandria and did that for 10 years. It was really-- you know, I say that I have been involved with two great organizations during my career-- the University of Michigan Medical School, and the American Society of Clinical Oncology. And to have the privilege of leading both of those organizations was just truly amazing. Well, there are many more things we could talk about, but for our listeners, you should know there's an Allen Lichter Visionary Leadership Award and Lectureship held at every annual meeting now. And for those of you who attend meetings at our headquarters in Alexandria, you'll notice you're sitting in the Allen S. Lichter conference center. Those weren't done by accident, by the way. They were done because of my guest today and all of the contributions he's made, not just oncology, frankly, but in my opinion, to medicine in general. As a dean, I know many of the things you've done, which we don't have time to get into. So on behalf of our listeners, and behalf of myself, and behalf of all the patients who have benefited through your work through the years, thanks so much, Allen. [INAUDIBLE] Dan, it was great being with you. Thanks for talking to me. Until next time, thank you for listening to this JCO's Cancer Stories-- The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts, or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories-- The Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org.

Dr. Hayes interviews Dr. Lippman discuss on being one of the first translational scientists in solid tumors.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Welcome to JCO's Cancer Stories, The Art of Oncology brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the role of cancer care. You can find all of these shows, including this one, at podcast.asco.org. Welcome to Cancer Stories. I'm Dr. Daniel Hayes. I'm a medical oncologist and a translational researcher at the University of Michigan Rogel Cancer Center. I'm also the past president of ASCO. I'm really privileged to be your host for a series of podcast interviews with the founders of our field. In this series of podcasts, I'm hoping I'll bring appreciation of the courage, the vision, and the scientific background among the leaders who founded our field of cancer clinical care over the last 70 years. I think that by understanding the background of how we got to what we now consider normal in oncology, we can work together towards a better future for our patients and their families during and after cancer treatment. Today, I am privileged to have as my guest on this podcast Dr. Marc Lippman. Dr. Lippman was really instrumental in the early studies of the role of the S receptor in breast cancer. And personally, I consider him with his former colleague Dr. William McGuire the first investigators to perform what we now call, quote, "translational," end of quote, science in solid tumors. Dr. Lippman was raised in Brooklyn. He received his undergraduate degree at Cornell where, by the way, he played on the varsity tennis team. And then he got his medical degree at Yale. He did his residency at Johns Hopkins and returned to Yale for a fellowship in endocrinology. Somewhat surprisingly, to me at least, he served a year from 1970 to '71 as a clinical associate in the leukemia service at the National Cancer Institute while simultaneously working in the laboratory of biochemistry with Brad Thompson, with whom he published extensively. Dr. Lippman has authored nearly 500 peer-reviewed papers. He co-edits Diseases of the Breast, which is considered the Bible of breast cancer with Dr. Jay Harris and Monica Morrow and Kent Osborne. And fundamentally, he has mentored the leaders of breast cancer in the world, in my opinion. Welcome to our program. Hello. I have a number of questions I'd like to ask you. First of all, clearly, you took a really unusual path to being a cancer doctor. To my knowledge, you actually never formally trained in oncology. Can you tell our audience how you went from being an endocrinology Fellow to being an oncologist? I think it's worth it, from my vantage point, to give a little background about me. I came from very, very intellectually rich family. And there was never any question that I was going to do some kind of science. I was certain that that's where I was headed. And when I was in medical school, I think it's important that while everybody was doing research at the school like Yale, a lot of medicine as we now think of it as evidence-based was completely mysterious. In those days, when I was starting medical school, really, I think the only fully scientific field was infectious disease because we had Cox postulates. And we knew what drugs killed what bugs. And we knew what bugs caused what diseases, for the most part. And that was wonderful. But endocrinology, at that time, was completely functional assays. It was completely not scientific. You looked to see if the rabbit ovulated or something like that for a bio assays. And Nobel Prize winning research was done, which developed the radio immuno and the radio receptor assay. And that completely transformed endocrinology over night. And within about one year, virtually every endocrine disease, the pathophysiology of Addison's, thyroid disease, you name it was worked out based on being able to measure minuscule amounts of hormones. And to me, this was fabulous. I was going to be an endocrinologist. I had no doubt about it. This was real science. And I could get into it. When I was in medical school, you had to do a thesis. And for reasons that I'm not even sure of now, I can recall, I got involved with a guy who was a hematologist. But he did work on leukemia. And I enjoyed that work greatly. It was very interesting. And right about then, you may recall, there was a minor episode going on called Vietnam. And many physicians or people who were about to become physicians, myself included, weren't very anxious to go to Vietnam. And one of the main alternative routes was to become an officer in the public health service at the NIH and to do your military service at the NIH. And that seemed like exactly what I wanted to do. It was a very unusual process. People at the NIH picked you for their own personal lab. And because I had been working in this hematology lab, a scientist, an administrator actually at the NCI invited me to join his lab, Saul Perry. And I took him up on that because that seemed like my only alternative. But after I finished my internship and residency and showed up at the NIH, because I was part of Saul Perry's group which was the leukemia service, I had to spend a year on the wards taking care of extremely sick people, most of whom died during that year. But because of my love of endocrinology, I kept studying all kinds of stuff around endocrinology, took the molecular endocrinology courses. And then I met this wonderful mentor, Brad Thompson. And my first project with him actually was an attempt to combine leukemia and endocrinology. And I started measuring glucocorticoid receptors in leukemia. And that's, frankly, some of the best work I ever did. We showed that they existed, that they were receptors, and that they predicted response. I mean, we did in leukemia what people were doing in breast cancer, and I thought that was pretty interesting. And there was always this tension in my mind between the science of endocrinology and the almost complete lack thereof, at that time, in oncology. And I thought that I might try to think about putting them together. But I needed to do formal endocrine training. So after I finished my clinical year at the NIH and my two years in the laboratory with Brad Thompson, I went back to Yale to do endocrinology. And I thought that's where I would complete my career. After I'd been there about a year, Paul Carbone called me up and said, would I like to come back to the NCI and join the breast cancer service? And I have to tell you candidly, I had never treated a case in breast cancer in my life when I went to join the breast cancer program at the NCI. And I completely learned everything I learned about breast cancer absolutely on the fly. So what made Dr. Carbone call you to do breast cancer? Well, I'm not absolutely certain. I had done well at the NCI. I'd been very interested in a lot of things. And I'm not certain I can remember anymore. I don't remember why Paul called me, but he did. And at that time, I had been looking at several endocrine jobs at a variety of institutions, including University of Chicago. And I was thinking I'd just spend my life as an endocrinologist. But I thought this was such a great opportunity to pursue my research that I decided to take my chances. I was extremely full of myself in those days. And I didn't see the problem that I had never treated breast cancer. I know it sounds dumb to say it. But I actually said, well, OK, I'll figure this out. How hard can it be? And I guess I didn't find it all that hard. And at that time, because I had already gotten into what I would refer to as molecular endocrinology, half of which was steroid-hormone action, I was highly familiar with the work of Elwood Jensen, who was the real pioneer at that time, one of two actually. So naturally, it made sense to me to take the work I'd already done in glucocorticoid receptors and try to make models in tissue culture for how breast cancer responded to hormones, the kind of thing you would never suggest that a newly minted faculty member try a completely insane project, which I was extremely fortunate that it succeeded. You refer to Elwood Jensen. Tell us more about Dr. Jensen and what he did that got you where you were. Well, Elwood was a tremendous scientist and basically a chemist. And people don't understand how technology sometimes makes a field possible. And just as I mentioned before, radio immuno and radio receptor assay made the entire field of endocrinology and now so many other subspecialties of medicine possible as you measure pulmonary and GI and cardiac hormones, in the same exact sense, what Elwood succeeded in making was radiolabeled steroids. And you can't do receptor assays unless you have high specific activity compounds. We don't use radio isotopes touch so much anymore, and people don't appreciate that. But there was absolutely no way to measure the binding in picomolar and centimolar ranges without high specific activity steroids. And Elwood was able to manufacture created hexestrol, which is a similar compound to estradiol. And with that, he was able to basically separate bounds from free hormone and prove the existence of receptors. It was extremely important studies that he did at the time. And it opened up the entire field of hormone dependency in breast cancer, which, up until that time, had been based entirely on clinical criteria for response. And furthermore, what occurred almost simultaneously with that was finally the invention of some serious drugs that could interfere with hormone action, most notably tamoxifen but several others that were synthesized at the time. And so rather than just having to oblate organs or use very toxic super pharmacological doses of steroids to treat patients with breast cancer, there was now a readily obtainable and usable oral therapy. And so there was a tremendous need to figure out how and why it worked. And a lot of people got into that field relatively rapidly. Bill McGuire being among them. James [? Whitless ?] being among them, myself for sure. And all of us felt that this was an extremely important aspect. There was the clinical aspect, which became clear in the early '70s that there was, as you would expect, a very, very nice correlation between the presence of receptors and response. And that led up to the entire opening of this field of now that you could measure these receptors of how they worked, where they bound, what they did, what genes they induced. And so that became a lifetime exercise for many. My impression is that before about 1970, endocrine therapy, which dated back the 1890s, was mostly done by the surgeons. Did you have to muscle your way into that field? Or were they openly agreeable that some guy who had never even did oncology would start treating breast cancer patients? Well, I think that what was going on then, in England, there was a much greater delay in medical oncology as a field. And these patients were still treated by surgeons and radiation oncologists. I don't think there was any parallel issue in the United States. There were some very wonderful pioneering surgeons, but they didn't, I think, pretend to fundamentally want to get into molecular endocrinology. I don't recall that as being an area of conflict in terms of doing these kinds of studies. And of course, in this country, we were unbelievably blessed by the extraordinary, absolutely extraordinary pioneering and organizational skills of Bernie Fisher, tremendous scientist, in his own right, a tremendous surgeon, but, even more importantly, the ability to really form the most effective, ragtag, co-operative group the NSABP, which was able, from its very inception, to do some of the most groundbreaking studies not just around hormone therapy, which they certainly did, but obviously as we all know about, differences in surgical care. And so-- You eluded to Dr. Carbone. My impression is the NCI, mostly, in those days, was all about leukemia and lymphoma, the so-called gang of five, MOPP and CHOP and Doctors Frei and [INAUDIBLE]. Who was behind you to move out and start taking care of patients with cancer in a more scientific basis? Was it just Carbone or were there other people at the NCI who [INTERPOSING VOICES] Well, shortly after I got, there Paul left. He went to Wisconsin. And Doug Tormey, who had been nominally head of the breast group, departed. And so I was suddenly given an empty stage and said, well, why don't you do it? So within two years, I was running a program in which, the previous year, I hadn't even treated a patient. It was extraordinary. But right about that-- I was-- that's a very good question and a slightly personal one. About 30. About 30, 31. Yeah. Most 30-year-olds now are just starting their residency or their fellowship. Right. And it is unfortunate that people with the most energy and most intelligence get increasingly pushed downstream. I mean, the age of first RO1s in this country is horrible, as we all know. And that's a major other problem that people need to address. But at that time, as you may recall, several groups were developing the first multi drug combinations for breast cancers. CMF, or as Johnny [INAUDIBLE] used to refer to it as CMF, and of course other variations with the MD Anderson regimens of so-called FAC chemotherapy, F-A-C, and other regimens that included vinca and prednisone. And so for the first time, reasonably active regimens were available for metastatic disease. Where in the past, it had only been a handful of single agents, vinca, methotrexate, 5-FU. And at the same time, I think there were the extraordinary, a little bit later, the extraordinary first data that adjuvant therapy was successful. I mean, the studies done by the NSABP initially was single agents and then the CMF studies from Milan were extraordinary. I mean, breast cancer was and remains the most tractable of the solid tumors with the possible exception of testicular that we've treated in this country or anywhere. Tell us about your lab work and how you established what you did, and then really interested in how you looked at what you were doing in the lab and said, jeez, this relates to my clinical work. Well, thank you. As I said, when I had been working at Yale before I came back to the NCI. And at that point, at Yale, I was trying to develop models of gluconeogenesis in liver cells. It had nothing to do with cancer. And so I arrived at the NCI, recruited by Paul, offered some laboratory space, and said, go to it. And I literally, literally scratched my head and said, well, what am I going to do now? And because I hadn't had a previous thing I was just going to expand on. And because another great miracle that had been growing from very late '50s to the mid '60s was cell culture. I don't think people can now imagine how pioneering the results were to grow cancer cells and to get them to reflect, in any sense, the phenotype of human malignancy. I mean, now we take it for granted. But these were pioneers trying to figure out how to grow cells, Harry Eagle and Hamm and Dulbecco, and all of these other wonderful people. So anyway, it seemed to me, wouldn't it be great, since someone had described a cell line that had estrogen receptor, I said to myself, what would be more straightforward than to figure out how you could manipulate these breast cancer cells with hormone therapies and figure out the mechanisms by using cell culture as a model for steroid hormone action? So I set about doing that. And after about six months, I succeeded. And that was the good news. And ironically, the better news was that nobody else could reproduce it, including Dale McGuire. And lots of people said this was, frankly, garbage, that I was making it up. And so when eventually-- no. It was very upsetting. I don't think many people when they first start off and they have their first big set of papers, and I published this stuff in Nature and serious journals. And all of a sudden, everybody says, it's not true. I remember giving a lecture at Harvard. And somebody at the end at the questions said, we just can't reproduce this data. We don't think you're telling the truth. I mean, how often you want to have that happen in your career? And as I said, what turned out to be very fortuitous was that we were right. And so eventually, that made things even easier for me in terms of my career. There's no question about that. And a lot of people wanted to go to the NIH. I think it's now with so many wonderful-- what are there more than three dozen comprehensive cancer centers? But the United States in those days, there were just a handful. And most of them were doing leukemia and lymphoma, like Stanford, which certainly had almost no breast cancer program at the time. And so people who wanted to work in breast cancer came to work with me. And lots of people wanted to get a BTA degree, Been to America. So I was fortunate to have some very outstanding people from Europe and Asia come to participate in my work. And there was still the tail end of Vietnam. So some of the very best and brightest, if I could misuse that expression, people like Neil Rosen and Ed Gellman and Doug Yee and George Wilding, people who all became cancer center directors were people that I was very fortunate to have work with me. And I was pleasured to deal with them. When did you say you were doing the lab models of cell lines and discovering how ER mediated the effects of estrogen? When did you start saying, let's take this over to the clinic? I mean, what was the first thing you did that you translated into the clinic? Well, the first translational study I did when I was a fellow when I tried to do correlations of response to glucocorticoids in leukemic patients and ALL and AML. So I mean, I was used to going back and forth that kind of way. And we did a series of drug trials in breast cancer patients. I was seeing patients. I haven't spoken much about it. But I don't know how to say that any other way whether it sounds modest or not. I simply love being a physician. I found that the main appeal of oncology was dealing with people at times of enormous obvious stress and disturbance in their lives. And I found that that brought out some of my best skill sets. And so I was anxious. I was always involved with patients like that. One of the main trials that we got involved with involved Allen Lichter because Allen and I were endlessly discussing what was the right therapy for localized breast cancer. You may recall that Sam Hellman, the joint center, refused to be part of clinical trials looking at lumpectomy and radiation, as he was convinced, turns out correctly, that that was equivalent to doing mastectomy. And we felt, Allen and I, I think somewhat maybe arrogantly again, that we could do a single institution trial for lumpectomy versus radiation. And we did. We ran a randomized trial of about 350 women at the NCI, a prospective randomized trial of lumpectomy and radiation versus chemotherapy. And of course, all of these patients became fodder for advanced disease trials and everything else we were doing. And those are some of the happiest days of my life working with Alan side by side in what may have been the first multidisciplinary clinic in breast cancer. If I may, I'm going to interject. Allen Lichter, who started the department of radiation oncology at the University of Michigan, where I'm sitting right now, was my dean when I arrived here, became ASCO president at one point, and then was the ASCO CEO for years. Since this is an ASCO publication, if you will, I'd give him credit for all of that. And well he deserves it. Well he deserves it. Yeah. I can't agree more with that. That's for sure. The other thing I've heard you-- by the way, I've always wondered. How did you get 350 patients onto that trial at the NCI, since you've tended not to see walk in the door kind of breast cancer patients, right? So how did you? Well, the NCI remember, everybody was treated free. So fortunately or unfortunately, given American medical economics, people who had a diagnosis would come to see us because they had no other option. We would pay all their travel and everything else. So we treated patients. And I have to tell you, up until last year when she died, I still had patients from that study who had followed me around the country to be treated. That's a great story. It's true. It's absolutely true. So the other thing I've heard you talk about, and I think people should-- given the proliferation of medical journals now, there's one on every corner, I've heard you talk about the fact that you really have a hard time finding places to present your endocrine results, that the Endocrine Society didn't care about cancer. And AACR didn't care about endocrinology. ASCO didn't really exist almost in those days. Give us some stories about that. Well, that's completely true. It's completely true. There was always a session in the Endocrine Society called cancer and hormones, which was late on Friday afternoon. And everybody had gone home. And AACR had the same thing. Because at that time, there just wasn't an obvious niche for cancer. What began to make it more popular to both societies were when things like, quote, "growth factors," close quote, became more in evidence. And they clearly played a role in cancer. But clinical trials and clinical experience had no role in the Endocrine Society. And basically studies in molecular oncology just didn't seem all that attractive to AACR. It wasn't like you couldn't talk about it. It just wasn't front and center what people were interested in. Everything goes through vogues periods. We're now going through an immunooncology voguish period. And I'm not trying to suggest that that's not extremely important and going to have endless value for people. But now, if you're doing almost anything else, you can't even write a protocol. It's true. It's true in some ways. I was trained. [INAUDIBLE], who's an endocrinologist, was at the Dana Farber and told me that cancer is just endocrinology gone wild. In fact, I believe, in many respects, that's what precision medicine is all about is that we begun to take what you guys did 50 years ago and said, let's do it for all the diseases other than immunology, which is a different issue. I agree with you. I think that that's a good point. I think that one of the fundamental differences between normal and cancer, however, is genomic elasticity. If you had psoriasis, and I put you on methotrexate. Then 10 years later, I doubled the dose, it would kill you. Because you never amplify the target gene, dihydrofolate reductase. And you remain sensitive throughout your entire life. Whereas doing that with a leukemic cell, in a couple of months, you'd be completely resistant. And that is, in my mind, one of the shortcomings of so-called precision medicine in which you're trying to match a pathway, an oncogene, to a specific therapy. In that, oftentimes, these studies are in end stage patients with multiple resistant clones now has become endlessly clear from single cell sequencing studies. And I think that there is, I think, personally, slightly less to most efforts in precision medicine than most people think. And I believe that it's amusing that precision medicine has come to include immunooncology, which has little, in my mind, to do with the initial way in which precision medicine was touted, which is find the oncogene. And we will give you the drug. And I think, by and large, that, except for some incredible successes like Gleevec for CML, hasn't really panned out. Personally, I think what we're going to do is head back to what doctors Hall and Frei and [INAUDIBLE] taught us, which is that resistance is a heterogeneous issue, and we need to combine drugs. We just need to do it more thoughtfully than perhaps we've been doing in the past. Couldn't agree more. I want to change the paths for just a moment. To my knowledge, you are one of the few and maybe you were the first oncologist who's been both a cancer center director at Georgetown's Lombardi Cancer Center but also a chair of medicine. You've been at two major academic centers, here at the University of Michigan and University of Miami. Why do you think there have been so few oncologists who have been chiefs of medicine, chairs of medicine? Well, your personal favorite institution, UT Southwestern, would be an example as well of a chair of medicine who's an oncologist. Right. But no particular reason comes to mind. I think that the skill sets and interests of a chair of medicine, at least as it used to be, up until maybe about 10 years ago, were someone who actually wanted to, A, have somewhat less of a research footprint, which would discourage some people, and something less of the same focus on curing a specific disease, which would certainly describe a cancer center director. And I think that exactly explains some of my clinical interest in becoming a chair of medicine at Michigan. I went there, there are always push and pull reasons. The push reasons were that Georgetown was economically a disaster. And they had sold both the hospital and the clinical practice to a large non-profit community-based hospital. And I thought that would be, more or less, the end of the cancer center as I knew it in. And unfortunately, that prediction turned out to be, in many ways, correct. So there was push issues. I just didn't want to officiate over the deconstruction of the cancer center that I had helped to build. And in addition, I felt clinically, I was raised in the era of great chairs of medicine. I was raised in the era of Don Seldon and Dan Foster and A. Magee Harvey, and people who knew everything and would teach at the bedside and knew everything about disease. And frankly, I felt that breast cancer clinically, not emotionally and not from a research point of view, but clinically is relatively straightforward and not that complicated. And I wouldn't say I was bored. But I was looking for a new challenge. And I thought the notion of really trying to bring other areas to bear in terms of my research would be fun. And so I was thrilled to be chair of medicine. But I don't think that's necessarily the career path that many oncologists or any other subspecialist would want. Which did you enjoy most, being cancer center director or being chair of medicine? Unquestionably, being cancer center director here at Georgetown. It was the thrill of a lifetime. When I came here, there were three people in the division of hematology, oncology. Two of them immediately left. And by the time I moved to Michigan, the Department of Oncology that I had created had more faculty than all of the basic science departments at Georgetown combined and more research money than all of the basic science departments at Georgetown combined. It was tremendously happy, very successful. And I felt we were doing really wonderful things. It was just a fantastic time, just like that, which is one of the reasons why I've come back. And I was going to say, although Georgetown did fall on hard times. My opinion is grown back into a major institution. And I'm sure they're happy to have you back. So we're running out of time. I really just touched the surface of many of your contributions. In addition to your scientific contributions, you really touched on it. You've been one of the most prolific mentors in our field in my opinion. I looked over your CV. I count at least six cancer center directors. I think five, four PIs and probably hundreds of others who are proud to have been under your watchful training eye, by the way, including myself, in our careers. So of all the things you've done, your science, your administration, your mentoring, we've touched on all three of those. How do you want people to remember Mark Lippman when it's all said and done? So there's a wonderful joke about that. These three guys are standing around saying what would they like to hear said around their coffin when they're dead. And one guy was a teacher, and he says, you know, I'd like them to remember what a wonderful teacher I was, how I helped people. And another guy's a physician, and I'd like to hear if I'm lying in my coffin, them say, what a wonderful physician. He did everything for his patients. The third guy says, what I'd like to hear is, look, he's moving. So it's hard to-- right. I am certain that the place that I feel most happy, it's not even a close call, is the ability to have played an important role in helping people's careers succeed. I mean, I'm something of a tough guy. But I have been, I feel, very willing to see people grow up and leave the nest and keep them nurtured and look after them for many additional years in their career and enjoy those relationships. It's incredibly enriching. Well, I also have to say there are hundreds of thousands, if not millions of women who have benefited from the contributions you and your colleagues made 50 years ago at the NCI and since then. I've tried to make it clear through all these podcasts how much we owe all of you for what you've done and where we are now. And the reason we're doing this is so people don't forget about those things as we move into medical economics and some of the other things that I think are less fun. So it's time to conclude here. I want to thank you for taking your time. And again, thank you for all you've done for the field, for those of us who've trained with you, and again, mostly for our patients. And I hope you've enjoyed this conversation as much as I have. Very much, Dan. Thanks for including me in this podcast. Until next time, thank you for listening to this JCO's Cancer Stories, The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or a review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe, so you never miss an episode. JCO's Cancer Stories, The Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org.

What do you get when you combine a professional wrestler, mutated amphibians, radioactive wastelands, and some hot, government-mandated lovin'? Just one of the greatest B-Movies ever. Roddy Piper stars as Sam Hellman, a rough and tumble adventurer who is reluctantly recruited to fight frogs, rescue maidens, and save humanity. These are the kinds of movies they just don't make anymore - because they probably shouldn't.

247Sports News desk managing editor and former Rutgers beat writer Sam Hellman joins Connor to remember what was and what could have been for Rutgers football. Also, more states threaten to pass Image and Likeness bills, and more trouble in Knoxville. All that and more on the 247Sports College Football Daily. Hosts: Connor Tapp, Trey Scott Find the 247Sports podcast for your favorite team here! Join the College Football Daily pick ‘em challenge on CBS Sports using the password “15minutesorfewer” and enter to win $1,000. Learn more about your ad choices. Visit megaphone.fm/adchoices

Restaurateurs talk about having skin in the game, but for Sam Hellman-Mass, the situation was more literal. In the buildup to opening Suerte—one of Food & Wine's 2019 Best New Restaurants—he had a stress-exacerbated allergic reaction to a medication that caused his whole body to turn red and his vision to be impaired for months. Still, he persevered, and from its inception, Hellman-Mass and executive chef Fermín Nuñez have set a culture at Suerte that puts the mental and physical wellbeing of their team and community first—all while making some simply masterful masa. During the recent SXSW Festival in Austin, Texas, Hellman-Mass sat down for an early morning chat about the sometimes scary shift from chef to owner, and how Suerte takes care of their own and the community around them. https://www.suerteatx.com Ig @suerteatx F&W Best New Restaurants: https://www.foodandwine.com/travel/restaurants/best-new-restaurants-2019

The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Welcome to Cancer Stories. I'm Dr. Daniel Hayes, a medical oncologist. And I'm a translational researcher at the University of Michigan Rogel Cancer Center. And I'm also the past president of ASCO. Over the next several podcasts, I am privileged to be your host for a series of interviews with the founders of our field. Over the last 40 years, I've been fortunate to have been trained, mentored, and frankly, inspired by many of these pioneers. It's my hope that through these conversations, we can all be equally inspired by gaining an appreciation of the courage, the vision, and the scientific understanding that led these men and women to establish the field of cancer clinical care over the last 70 years. By understanding of how we got to the present, and what we now consider normal in oncology, we can also imagine and work together towards a better future, where we offer patients better treatments, and are also able to support them and their families during and after cancer treatment. Today, I am very pleased to have as my guest on this podcast, Dr. John Minna. John is generally considered one of the pioneers of translational research in solid tumors, and he's widely recognized as a leader in lung cancer. Dr. Minna is currently the director of the Hammond Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at the University of Texas Southwestern Medical Center in Dallas, where he also holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. Dr. Minna received undergraduate medical degrees from Stanford in the mid-1960s, which were followed by a residency at Harvard's Massachusetts General Hospital in Boston. He then went to the NIH, and the National Heart, Lung, and Blood Institute for his fellowship in biochemical genetics at the NIH with Dr. Marshall Nirenberg. And then he stayed at the NHLBI as the head of the section on somatic cell genetics. In 1975, he became chief of the NCI-VA Medical Oncology branch within the Clinical Oncology program of the Division of Cancer Treatment. And in 1991, he then moved to University of Texas Southwestern in Dallas, where he served as the director of the Sammons Cancer Center and Chief of the Division of Medical Oncology for four years. And since, he has held his current position. Doctor Minna has authored over 700 peer-reviewed papers, and well over 100 other reviews, book chapters, and educationally related manuscripts. He's won too many awards and honors for me to go through in detail. But these include the AACR's Rosenthal award, and ASCO's Scientific Achievement Award, two of the highest in those two organizations. He's also received the ASCO Statesman Award, and he's served on both the AACR and the ASCO boards of directors. He's been PI of the combined UTSW and M.D. Anderson Cancer Center Lung Cancer Specialized Program in Research Excellence. And in 2015, he was named one of the Giants of Oncology by OncLive. Dr. Minna, that's quite a mouthful, though. Welcome to our program. Thank you so much, Dan. And thanks for all your work in ASCO and everything, too. Well, actually, it was, as you can imagine, a great privilege. I just had a fabulous time. Just as an aside, when I got elected, I interviewed about 10 former presidents. And at the end of each of my set of questions, I said, well, fill in the blanks. What do you want to talk about? Almost everyone of them said the saddest day of their career was the day they had to quit being president of ASCO. And I know that now. Anyway, now I know you went to Stanford. Were you always a California boy? Or how did you get to Stanford? Well, yes. I was born in San Francisco, actually at the Presidio, which is now a fancy movie set-- some of the priciest real estate. And then, my dad was in the Army. My mom was a nurse. And then I grew up in San Diego. And my Dad had the largest family practice in San Diego. And my mom was the nurse that ran the office. I never forget, I called them one day when I was an intern at Mass General and complained I had 25 outpatients that I saw that day. And they laughed. They'd seen 80. And I made maybe 500 house calls with my dad, carrying his bag when I was younger. And so, he obviously was in medical school just before and then right after the Depression. And so, he had had an opportunity. He was going to do a fellowship in pediatrics at Harvard, but couldn't do it. He had to support all his parents and everything. And, by the way, he had immigrated from Italy when he was a kid. So this was quite a story. And so they always encouraged me to go into academic medicine. It was interesting, because all his buddies were surgeons that kept telling me to come back and be a general surgeon in San Diego. So anyways, I grew up in San Diego. And then was lucky enough to get into Stanford undergraduate medical school. So I went back and looked at your publication list, which dates back to the mid-1960s. By the way, I was in junior high then. It looks to me from your list of publications that you weren't originally headed to a career in oncology. In fact, it looks like you were doing genetics. So you've done a lot in lung cancer. Tell us what happened at the NIH that you sort of changed gears and went into lung cancer. Well, actually, the cancer decision was actually made back in medical school. And it was those-- two of the people that you mentioned when we were talking before, Henry Kaplan and Saul Rosenberg, that really inspired me at Stanford. And they both took me under their wing. I remember the last six months of medical school I spent full-time on radiation oncology. Actually, I worked up nearly 100 new patients with Hodgkin's, if you can imagine that. It's all because of the clinical trials going on there at Stanford. So there were all these new patients coming in. So both of them absolutely got me committed to a career in cancer way back in medical school, and then helped get me internships, residencies. It was Henry's letter to get me a position with Marshall Nirenberg. But both of them were instrumental. And they took a group of young people-- another person that was a year behind me was Ron Levy, obviously, a very prominent person in oncology. And there was a group of us at Stanford that they took under wing. And so as medical students, we were going to these clinical protocol conferences in cancer, which probably didn't exist anywhere else in the United States at that time. And it was just amazing to see the two of them work together-- totally different personalities, but extremely skilled clinically and in terms of clinical trials. So that was an exciting time. And so the decision for me was made way back there when. And as part of it, at Stanford Medical School, I was fortunate enough to do my research in the Department of Genetics. And the person that took me under his wing there was Leonard Herzenberg, who was the guy that invented the fax machine. Obviously, probably should have won the Nobel Prize for that. And so it was kind of genetics on the one side, and cancer on the other. So you can see how that kind of evolved going forward. What struck me at Mass General was that there were fantastic clinicians and everything. Obviously, a lot of cancer. But nobody wanted to take care of the cancer patients in Mass General. So an intern resident, I kind of volunteered for all of that. And then when I got to the NIH with Marshall, it was more genetics and everything. And we can talk about that. But I realized after five to seven years there I was either going to be a basic researcher, or get back to my clinical love. And that would have been cancer. So those were the ties that brought genetics and cancer together for me. So can I ask you, when you were in Boston, who was the chief of medicine at Mass General? Oh, gosh. [INAUDIBLE]. The real question I'm asking is, had Dr. Farber's work filtered across town to you guys? That was just about the same time he was starting to give chemotherapy to kids over at Children's. Right. No. Obviously, they knew about it. But it really wasn't discussed at all there. And there was obviously a separation between what was going on at Farber and the Brigham and then at Mass General. Now, obviously, things are much more integrated. So what made you go into lung cancer after you got to the NIH? I think it was Vince DeVita. But it happened because I actually-- so I'd been with Marshall and they had given me my own group to work with there that we mentioned. And I'd been working on somatic cell genetics. And so I went to Vince and I said, look it, I have to do an oncology fellowship so I can learn about this stuff now and get ready. Of course, this is-- the boards came in '75, which were later. And so he said, well, John, I'm not going to do that. But I tell you what. There's this branch of the VA hospital that [INAUDIBLE] [? Anson ?] and Frank [INAUDIBLE] and [INAUDIBLE] are running. And I'm trying to decide whether or not to shut it down. So I tell you what. Why don't you go down and run that? And then you'll kind of learn on the job. And, of course, being 35, 36 years old, you think you can do everything. And I said, well, who's the staff there? And he said, well, they're all leaving. And fortunately, one guy [AUDIO OUT]. So I said, well, who are the fellows coming out of the program that are the best fellows? He said, well, that's easy. It's Dan [INAUDIBLE], Paul Bunn, and Jack McDonald. And so I said, well, if I go talk to them, will you at least back me up? And so I did. And fortunately, two of the three agreed to come. I said, you're going from being a fellow to being a senior investigator here in one fell swoop. But this is it. Jack went with Phil [? Stein ?] and did all the work on GI. Phil was leaving the NCI to go down to Georgetown. So they did that. And fortunately, Marty Cohn was down at the VA. He is fantastic clinical trials [INAUDIBLE] and done work with lung cancer. And we did all of that. And so, we went down there. And so, I said, well, OK, got to work on lung cancer. And so we've got to then start working on the genetics of lung cancer. Of course, everybody said that was totally stupid and not possible. And fortunately, I had my collaborator who had been part of the oncogenic virus program, a pathologist, Dr. Adi Gazdar [INAUDIBLE]. So I said, Adi, come on down, and we can do that. So there was people that really gambled on me. Yeah. I wanted to talk about your association with Adi. Before I get to that though, what were you doing for lung cancer in the mid '70s? It must have been pretty crude. Well, we thought it was pretty sophisticated. And, in fact, what we-- obviously, there was the whole series of the first phase of small cell lung cancer clinical trials. There were first reports that occasionally patients respond, have these dramatic responses. And so we set up these whole series of trials. And, of course, at that time, nobody out in the private world wanted to take care. So these patients would come flooding in. And we would do all the staging, get their tissues, and then try to start cell lines from them that nobody had been able to that before. But then they all went on to randomized clinical trials. And Marty Cohn played a big role in that. Obviously, Dan [INAUDIBLE] and Paul Bunn were instrumental. Des Carney came on. And so, these were various combination therapies that [INAUDIBLE] essentially leukemia-like treatment. But Vince always thought the reason we weren't in small cell lung cancer was that we weren't tough enough. And I kept saying, Vince, we're getting-- we're putting them in isolation. We're treating them with more intensive regimens than with leukemia. And so odd responses, but not. And then the other important component of that was Eli Glatstein's recruitment to the NCI as head of the NCI radiation oncology branch. And he really was-- I mean, briefly had known each other at Stanford. And because we were both tied to Henry Kaplan, that made Eli and me instant friends. And basically, we were like brothers. And so he totally threw the support of the radiation oncology branch behind that. And then there were a series of trials with that. Allen Lichter, former president, obviously, and Joel Tepper, he [? added ?] parts to that. So that was fantastic. Anyone from-- So it must have been pretty exciting for you to see some of the first complete responses with chemotherapy in a solid tumor with a small cell. Absolutely. And that's what-- you know, at that time, and particularly then when we started putting this with limited stage, we were really hoping there was going to be a big tail on the survival curve with people who got put into complete remission being able to remain there. And obviously, the therapies would combine modality with chemo and radiotherapy were complex, too. And we were very fortunate to have the various skillful skill set from the radiation oncologists to work with that. And then in '81, by the way-- so we were at the VA from '75 to '81. And then from '81 to '91, it was the NCI-Navy Medical Oncology Branch, when Vince moved us all up to the new National Naval Medical Center. So you and Dr. Gazdar obviously have had a decades-long collaboration. And how did the two of you even hook up? Was it just because you were providing specimens to him in the pathology lab? Or-- No, no. It all actually started five or six years before. We were-- as part of the somatic cell genetics effort is-- I don't know if you remember, there was also a big effort in terms of isolating tumor viruses and the study of retroviruses. And it turned out that the genetics that I was doing with somatic cell genetics could be used to map receptors for retroviruses. And so he and I collaborated on studying the genetics of RNA viruses in human cells and assigning the various linkages to different chromosomes. And so when, again, as I said, when Vince offered me this battlefield promotion, I knew were going to need a laboratory thing. So I said, Adi, come on down. I said that we were going to have to-- we can't study viruses. We're going to need to study something else. And it's going to probably be lung cancer. And so he agreed. And obviously, he has trained as a pathologist, even better part. And he's now, obviously, one of the world's leading lung cancer pathologists. The other person that was at the VA whose name you may not know is Dr. Mary Matthews, who is a pathologist. And she did a lot of the first VA studies, actually determining that small cell lung cancer was highly metastatic, even when it appeared to be localized. So she was-- I've seen her work. Yeah. Actually, so you were there when viruses were going to be the cause of every cancer. Did you get a lot of pushback if you began to say, I don't think that's the case? Well, it's kind of what goes around comes around. We didn't-- no. As it turned out, it was oncogenes that are cause of cancer, which were discovered through Bishop and [INAUDIBLE] thing too. But you do know the other interesting connection with us and viruses and cancer is that we were obviously studying lung cancers and patients and that. But then, Paul Bunn was extremely still interested in lymphomas. But the way the politics, the Onco politics at the NCI intramural program went, that was already the domain of the medicine branch, Bob Young's branch-- Bruce [? Jander ?] and Dan Longo and Bob Young. But there was one lymphoma that they absolutely wanted to have nothing to deal with. And that was Sézary syndrome mycosis fungoides. So Paul said, OK, we're going to study mycosis fungoides. So both at the VA and at the Navy, we had just huge numbers of patients with [? MF ?] come in. And that involved a variety of studies with electron beam and various therapies and staging that Paul was a major figure in. Well, as part of that-- so we started cell lines, tried to start cell lines from those as well. Well, the other thing that was happening was Bob Gallo's discovery of IL-2, T-cell growth factor. And so we got some of that from him, and were able to study, to grow several of these. And it turned out, one of these was from a young patient with highly aggressive HTLV-1 disease. It was a young black guy from the South. He had one of the first-- you know, his bone scan was a super scan with [INAUDIBLE]. Now, we know. So we didn't do that. And it turned out that Bernie Poiesz was a fellow rotating with us. And he went back to work in Gallo's lab and took those cells. And, of course, Gallo was searching everywhere for oncogenic viruses and retroviruses. And the super [? agent ?] from this cell line, H102, blew the roof off. And it turned out to produce HTLV-1. And that was [INAUDIBLE]. Actually, Henry Kaplan submitted for us to PNAS that was with Bernie and Bob Gallo. And that was the first human retrovirus that was discovered. And then it turned out there were other patients that we had, obviously with T-cell lymphomas, that didn't produce virus. But it turned out that those were ones that the virus could replicate in. And that leads off into a whole separate story that you probably need to talk to Adi Gazdar about, because he started this line. And that's the whole Bob Gallo thing. But the point is that Bob knew that if you could get a T-cell line to grow, it could make the retrovirus, and you could identify it. And so, he kept trying to grow T-cells from patients, at that time young, gay guys from New York and San Francisco. Of course, nothing would grow because they were all being killed by HIV. But there were these T-cell lymphoma lines that had that property. So, in any event, this whole thing came back to viruses, that-- it's not my [INAUDIBLE] study. But it was Adi's and Bob Gallo's. You know, you've through this talked a lot about the basic science and the observations. And the term translational medicine really hadn't been invented yet. But you, and I would argue, Marc Lippman and Bill McGuire in breast cancer, were really some of the first to span the gap between [INAUDIBLE] in the clinic in solid tumors. My impression is leukemia and lymphoma had been going on, but it was the solid tumors where you made your big step. Were you thinking about that the whole time? How can I take this and take better care of Mr. Smith or Mr. Jones? Were people trying to stop you from doing that? Who was your role model to give you the courage to move forward? No. I think if you were present back at the NCI-VA and NCI-Navy, it was pretty clear-- and this didn't require any set of smarts-- that the whole idea to start these things was to have models that you could then test to see about new therapies in order to find out what were the underlying causes. And so you remember back there was the [? Amberg ?] and Dan Von Hoff assays for tumor cell sensitivities. So a lot of our first studies were looking at drug response and radiation response phenotypes. And one of the interesting first things was that the small cells, most of them were exquisitely-- they were like lymphocytes, sensitive to radiotherapies, which was what it was like in the clinic. So I think that there was probably kind of obvious some of the things to do. I think the obstacles were-- first of all, the major obstacle was everybody blamed the lung cancer patient for having lung cancer because they smoke. And I'm sure Franco and anybody working in the lung cancer field with Franco Muggia would tell you this. And we're finally over that, I think, and also with the never smoking lung cancer cases. So that was one big obstacle. I think having these models to work with was another. And then just having the genomic techniques to study them. I look at our first publications in Nature with Southern blots and a few samples. And now, you couldn't even-- this wouldn't even qualify as supplementary supplementary data. Actually, I don't know if you were at ASCO. Bruce Johnson's presidential address was an elegant description of the progress made in lung cancer. And he showed pie charts of 10 years ago. And the entire treatment was chemotherapy. And now it's broken up into all the different precision medicine and immunoncology. I've got to think if you were in the audience, and if you weren't, that's fair. But if you were sitting here thinking, boy, shake my head. We've made a lot of progress. Oh, [INAUDIBLE]. Well, I tell you, I get-- some of those slides I know Bruce was-- I was giving those to Bruce. So, you know, clearly, those were the types of obstacles. And everybody thought that-- first of all, everybody thought that lung cancer was not a genetic disease. And in retrospect now, it's obvious. But, you know, so I think there's that-- the technologies. So one brief anecdote about-- and you probably saw this, too, at the Farber. I'll never forget at the NCI-Navy, all of the senior staff rotated. And we had several months worth of attending in there. And we were taking care of patients with all kinds of tumors-- breast, lung, everything. And we had our own ward with 40 beds. And we saw about 70 patients elsewhere in the hospital. And we had 100 patients a day in clinic. So it was a huge service. So I go up, and I'm doing my first day of attending. And I introduce myself. And I'll tell you who my fellows were on that round. So one of them was Nancy Davidson. The other was [INAUDIBLE]. The other was Neal Rosen. And one was George Morstyn, who subsequently became a-- Australian guy became a VP at Amgen. And so they're presenting these cases and everything. And I go back, and I sit down with Paul and [INAUDIBLE] and Dan [INAUDIBLE]. And I say, Jesus. I said, I can't believe it. We have some really good fellows this time. At another time offline when it's not recorded, I'll tell you some of the presentation that Neal Rosen gave that time, which was vintage Neal. And I say this mainly because to our oncology fellows now, I say, look right, look left, and there's going to be some really interesting people that you're meeting right now. Just remember them several years down the line. You know? Nancy was no different in her presentation today than when she gave her presidential address. She had all the [AUDIO OUT] and everything. And so, that was great. Nancy and I are the same age, but she's been my role model for 25 years. [AUDIO OUT] The other thing-- Well, a couple of other questions-- you've been on the board of both the AACR and ASCO. And I'm interested in what you see as both the contrasts and the mutual initiatives going forward and how they've evolved. Do you have any insights into that? Well, I think Saul Rosenberg may have said something about this [INAUDIBLE] to you. He always, from early on, lamented that, quotes, "commercialization" of ASCO, as opposed to its academic thing. I think, number one, ASCO has done a fantastic job in terms of medical education at many different levels. So I think that's a major success. I think also what clearly is needed now is that we get more of the real world experience. So if patients are treated with checkpoint inhibitors with lung cancer, we don't need to know the results of 300, or 400 patients, or 500. We need to know what happens in 10,000 or 20,000 patients. And the only way we're going to get this is to have some kind of interaction with everything that's going on in the real world. And I think ASCO is positioned to do that. And so, I see that type of interaction being very important. Back when I was on the board, there was-- well, how many people from the private sector should be on the board? And we need to have them have a voice, and all of this. And there was kind of the-- then some people in the private sector trying to take control of ASCO for their own group practices. And we won't go into any names or anything here. But I think what's eventually come out is the possibility to really be the best for everything, both educational, translation of findings. So if there's real improvement in discoveries which have happened to be made, we obviously want to get them out as quickly as possible. Patients demand it. But then also, that we can work out some way to get feedback. Actually, this is one of the reasons-- you've hit on a couple of big initiativies over the last 10 years that I've been involved with. One is the development of CancerLinQ. And we hope that CancerLinQ will provide exactly the kind of data you just asked for. The other is the establishment of the Department of Clinical Affairs, and reaching out to the state-affiliated councils. Steve Grubbs is our Vice-President for that. And it's made a big difference. So that instead of being us versus them, academic versus private practice, it's us versus cancer all together. I'm glad you noticed that, actually. One final question, and this is a bit of a trite question. But I'm asking each of my guests on the show, what do you consider your legacy, your greatest accomplishment? In the end, what are people going to remember John Minna has done to change the face of oncology? Is it your science, or your mentoring? Or what's the one thing you would put your finger on? Well, I think Bob Young and I have an agreement about this. It's the mentoring and everything. And I think training the next generation, setting the example, is very important. I would say one other thing that's really important about ASCO that I see going forward is integrating surgery, radiotherapy, other disciplines, too. And I think it's been very successful. It wasn't necessarily all that way at first. But it's been really key. And getting a chance to know some of the giants in surgery and giants in radiation oncology, like Sam Hellman and Eli Glatstein. And I think Vince, in his book, in many ways saw that, too. The DeVita textbook with Hellman and Steve Rosenberg was an important example of that. So I think that's another important legacy from ASCO too. I agree. Well, actually, I think we've run out of time. Dr. Minna, I can't tell you how much I appreciate your taking the time to speak with us today. I'm sure the memberships can be thrilled to listen to the stories you've told. It's interesting, you've referred to several people I've actually already interviewed, or have planned to interview in the near future. You dropped a lot of names. And that's because-- and you sort of alluded to this. I'm not sure any of us recognize where we are in history at the time that history is being made. And then you look back and say, wow, I was there. And that you were fortunate to be at the NIH in those days. I was fortunate to be at the Dana-Farber in a few years after that. And you shed a lot of light. It's been terrific. Any final comments or parting words? Well, no. I think the one thing I would say is I was thinking back to those early ASCO meetings where there would be 5,000, 7,000, 8,000. So you couldn't even walk from one place to another, because you were always stopping and talking. And now you go to 15,000, 17,000 more. And I remember John Niederhuber and I, when he was director of the NCI, on the third day of ASCO walks through and he grabbed me, and he said, John, you're the first person I recognize. And I [INAUDIBLE]. We had roughly 40,000 people at the meeting this year. Yeah. I think that the question-- so going forward is how we need this family, but how do we get it so it could also be on the personal level? Anyway, Dan, it's been good talking to you. And we thank you for your service, Dan. Thank you. It's been great. For more original research, editorials, and review articles, please visit us online at JCO.org. This production is copyrighted to the American Society of Clinical Oncology. Thank you for listening. [MUSIC PLAYING]

Hailing from Boston, MA, and a Graduate of Boston University Questrom School of Business,  Sam Hellman-Mass has previously worked at the Montagna Restaurant at the Little Nell Hotel in Aspen, where he met Bryce Gilmore and later moved to Austin and helped him open Barley Swine, and Odd Duck. Under Hellman-Mass's leadership, The Odd Duck received much acclaim. With this success in his back pocket, in 2017 Hellman Mass broke off on his own to open Suerte, a Mexican restaurant specializing in house-made masa . Just this past year Suerte was one of 50 Nominees for Bon Appetit's "Best New Restaurant." Show notes… Favorite success quote or mantra: "If you do what you love and what you're passionate about, you'll always end up finding the most success." In this episode with Sam Hellman-Mass, we discuss: How to follow your passion. Going after what you want, head first. Making the most of your job experiences by asking questions, being curious, and constantly creating learning opportunities for yourself. That when you take the time to be the teacher you eventually become a master. How to balance being a boss and a friend with relation to your team members. When managing relationships, coming from a place of caring. How working hard doesn't only create opportunities, but it also improves your skill, making you even more valuable. Having a way to settle disputes in a partnership. It could be a system or a personal that determines the final outcome. Advice for managing partnerships. Advice for managing team members. How you'd be surprised at what people would be willing to share with you if you show an interest in them and what they're up to. Focus on being the best at one thing. Have a "Unique Selling Proposition". Be mindful of the story you are telling on your quest to be the best. Use that story to develop your brand. Build a restaurant where you have roots. When making financial decisions for a restaurant, keep them simple. The benefits of being empathetic, open minded, and considerate of other peoples feelings and thoughts. Today's sponsor: Gusto offers modern, easy payroll, benefits, and HR to small businesses across the country — they were even named best online payroll by PCMag. And as a listener, you'll get three months free when you run your first payroll. Sign up and give it a try at Gusto.com/unstoppable.  BentoBox helps restaurants grow their business through a connected suite of tools, offering them an integrated website to connect with their guests and drive revenue online. Restaurant owners and operators are able to easily update menus, promote specials, take catering and event inquiries, sell merchandise, gift cards and more. Revel Systems integrates front of house and back of house operations into a single dashboard. Designed to increase security, stability, ease of use, and speed of service, Revel's streamlined ecosystem provides businesses with the right tools to grow. Learn more at revelsystems.com/unstoppable. Knowledge bombs Which "it factor" habit, trait, or characteristic you believe most contributes to your success? Following his passion. What is your biggest weakness? Being annoying. What's one question you ask or thing you look for during an interview? Will this person still be here when it gets tough? What's a current challenge? How are you dealing with it? Trying to keep his people happy. He's combating this by constantly asking his people what they want/need. Share one code of conduct or behavior you teach your team. Be nice to people. What is one uncommon standard of service you teach your staff? Try to make it a "yes." What's one book we must read to become a better person or restaurant owner? GET THIS BOOK FOR FREE AT AUDIBLE.COM  Setting the Table: The Transforming Power of Hospitality in Business.  What's the one thing you feel restaurateurs don't know well enough or do often enough? Take a day off. What's one piece of technology you've adopted within your four walls restaurant and how has it influence operations? Hotschedule's Messenger Board.  If you got the news that you'd be leaving this world tomorrow and all memories of you, your work, and your restaurants would be lost with your departure with the exception of 3 pieces of wisdom you could leave behind for the good of humanity, what would they be? A good meal always starts with good ingredients. Serving food that fulfills you, first. Be nice. Contact info: suerteatx.com Thanks for listening! Thanks so much for joining today! Have some feedback you'd like to share? Leave a note in the comment section below! If you enjoyed this episode, please share it using the social media buttons you see at the top of the post. Also, please leave an honest review for the Restaurant Unstoppable Podcast on iTunes! Ratings and reviews are extremely helpful and greatly appreciated! They do matter in the rankings of the show, and I read each and every one of them. And finally, don't forget to subscribe to the show on iTunes to get automatic updates. Huge thanks to Sam Hellman-Mass  for joining me for another awesome episode. Until next time!   Restaurant Unstoppable is a free podcast. One of the ways I'm able to make it free is by earning a commission when sharing certain products with you. I've made it a core value to only share tools, resources, and services my guest mentors have recommend, first. If you're finding value in my podcast, please use my links!

Sam Hellman Mass is not only known for his amazing food, but now his business sense. With three successful projects in Austin Sam pushed the envelope and helped make Farm to Table a house hold term in Austin. His fascination with amazing ingredients and making the most out of what you have in the kitchen has resulted into a delicious empire. Guests: Sam Hellman MassHost: Dan Dillard, Ryan FrancisProducer: Myrriah GossettMusic by: Scott HolmsFounding AustinMasters and Founders Facebook Group See acast.com/privacy for privacy and opt-out information.

Welcome to the Rutgers Scoutcast, a Scarlet Knights podcast on the 247 Sports network. In this episode, Sam Hellman of Scarlet Report and national recruiting analyst Brian Dohn look ahead to the early signing period. 0:00 – Open 3:35 – Jalen Jordan Commitment Impact 13:20 – Rutgers Football in 2017 18:30 – Garden State Hardwood Classic SOLD OUT 27:00 – Close – 30 – 

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews Rutgers AD Pat Hobbs about the Chris Ash contract update and more. Also, hear an exit interview with tight end Myles Nash ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 4:10 – Pat Hobbs Interview 13:45 – Myles Nash Interview 21:30 – Rutgers Scoutcast Mailbag and Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews defensive end Kemoko Turay before his final college game. Brian Dohn stops by for the news and Jerry Kill offers his sage advice in his final comments of the season. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 5:15 – Kemoko Turay 10:40 – In-Depth With National Analyst Brian Dohn 29:00 – Rutgers Scoutcast Mailbag 34:50 – Jerry Kill & Close 

The Rutgers Scoutcast is a weekly podcast for fans of all varieties. In our latest edition, four-star IMG quarterback Artur Sitkowski goes 1-on-1 with Scarlet Report about flipping his commitment to Rutgers and a return home to New Jersey. Afterwards, national recruiting analyst Brian Dohn and Sam Hellman break down this week in Rutgers news. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 3:15 – Artur Sitkowski Interview 14:15 – Rutgers Basketball is 3-0 23:45 – Rutgers Football is 4-6 33:30 – Chris Carlin to WFAN Afternoon Drive 39:15 – Rutgers Scoutcast Mailbag – all-time players and annoying announcers 0:00 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews wide receiver Mohamed Jabbie about his rise to a starting role. Then, Hellman and national recruiting analyst Brian Dohn go into full detail about the four-star flip from Miami to Rutgers of quarterback Artur Sitkowski. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 2:55 – Mohamed Jabbie Interview 9:05 – Full Artur Sitkowski Breakdown 27:15 – Rutgers Scoutcast Mailbag – Quarterback Coaches and Halloween 35:15 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews basketball captain Deshawn Freeman live from Big Ten Basketball Media Day at Madison Square Garden. Freeman discusses his leadership transformation at Rutgers and tournament aspirations. In the news, national recruiting analyst Brian Dohn joins the show for a full Rutgers breakdown. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 4:35 – #TheCaptain Deshawn Freeman Interview 13:50 – Scout on the Road, 2019 five-star 22:00 – Zamar Wise vs. Ta'Quan Roberson 27:35 – Two-Game Win Streak 31:25 – Rutgers Scoutcast Mailbag – Practice QB Debate & Halloween

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman is with you from Madison Square Garden where he speaks with head coach Steve Pikiell. After 10 good minutes with Pikiell, the Rutgers Scoutcast hits the news with recruiting and football conversation.  ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 2:55 – Rutgers Coach Steve Pikiell 17:35 – Amad Anderson Decommitment 26:15 – Scout on the Road 34:15 – Jay Harris Plays Safety 38:00 – Rutgers Scoutcast Mailbag – Basketball Polls and Paying Players 48:15 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman visited Baltimore Calvert Hall for a conversation with head coach Donald Davis. Davis coached Rutgers freshman Tyshon Fogg and coaches 2018 offensive line commit Reggie Sutton. After that, CBS national recruiting analyst Brian Dohn joins the show to talk recruiting, development and more. AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 5:00 – Calvert Hall Coach Donald Davis 16:05 – Scout on the Road 26:35 – Mid-Year Rutgers Development 35:05 – Rutgers Scoutcast Mailbag 39:10 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman sits down  with CBS recruiting analyst Brian Dohn to discuss the Rutgers bye week, a 2019 commitment and two more decommitments in the 2018 recruiting class. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 4:50 – Scout on the Road 13:20 – Zamar Wise Commitment Profile 15:50 – Scarlet Report Merger 18:30 – Decommitment Discussion 24:50 – Rutgers Scoutcast Mailbag – Bo Melton and Fall TV 33:10 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews two of the best wrestlers in New Jersey high-school history -- Rutgers' Anthony Ashnault and Nick Suriano. After the two break down their offseasons and more, Scout national recruiting analyst Brian Dohn joins the show for Scout on the Road and much more. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 4:15 – Anthony Ashnault Interview 12:35 – Nick Suriano Interview 17:50 – Scout on the Road with Brian Dohn 28:15 – Blessuan Austin's ACL 32:35 – Return of the King, Greg Schiano Stories 44:00 – Rutgers Scoutcast Mailbag – NCAA Basketball Scandal & Campus Diner 55:25 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews Ashley Bragg Ryan about her time as an Olympic athlete before she married former star football player Logan Ryan and devoted herself to animal rescue. After, Scout national recruiting analyst Brian Dohn is here to break down the latest news in Rutgers country. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 4:15 – Ashley Bragg Ryan Interview 20:30 – Scout on the Road 31:00 – Freshmen on the Field 36:30 – Almost Basketball Season 42:35 – Rutgers Scoutcast Mailbag – Ash Hire and the Brain 48:45 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews a trio of Rutgers freshman linebackers before an in-depth, and heated, discussion with Scout national recruiting analyst Brian Dohn. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 5:35 – Linebacker Round Table, Syhiem Simmons 9:20 – Linebacker Round Table, Olakunle Fatukasi 13:05 – Linebacker Round Table, Tyshon Fogg 17:15 – Scout on the Road 24:00 – Jerry Kill & Eastern Michigan Aftermath 34:30 – Rutgers Scoutcast Mailbag – Quarterbacks, Angry Brian and Dogs 42:40 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews Rutgers safety Saquan Hampton, who is fresh off a defensive MVP award from his head coach. Hear about Hampton's tough road to a starting role before Brian Dohn joins the show for your weekly news and analysis ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 3:20 – Saquan Hampton Interview 9:35 – Scout on the Road 16:40 – Rutgers vs Washington Impressions 24:15 – Larry Stevens Earns Scholarship 28:05 – Rutgers Scoutcast Mailbag – Marcellus Earlington & Holiday Weekends 34:00 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman interviews a pair of Rutgers staff members, starting with co-defensive coordinator Bill Busch and followed by strength and conditioning chief Kenny Parker. Scout national recruiting analyst Brian Dohn joins the show for our weekly news segment. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 5:25 – Bill Busch Interview 14:40 – Kenny Parker Interview 19:00 – Chris Laviano Saga 26:20 – Matthew Thomas Commitment Breakdown 31:10 – Tavon King Commitment Breakdown 37:50 – Rutgers Scoutcast Mailbag – Defensive Line & Soccer Stuff 45:15 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman greets a fellow podcaster from the Rutgers community. For Rutgers graduate assistant Drew Lieberman is now the full-time receivers coach at his alma mater, and has an excellent podcast with co-host Gary Nova. Hear Lieberman's story before a detailed breakdown of the Scarlet Knights' depth chart with analyst Brian Dohn. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 4:40 – Coach Drew Lieberman from the Sideline Hustle Podcast 20:45 – Depth Chart Breakdown with Brian Dohn 55:45 – Rutgers Scoutcast Mailbag – Boxing and Breakthroughs 63:15 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes Scout director of basketball recruiting Evan Daniels and Trentonion sports editor Kyle Franko. Daniels offers his expert take on Rutgers' August surge, including the commitment and breakdown of four-star Montez Mathis. Franko shares his Mercer County Rutgers stories and has some fun talking Daily Targum. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 7:10 – Evan Daniels Interview 17:30 – Rutgers Football with Brian Dohn 25:30 – Rutgers Scoutcast Mailbag – Program Faces & Zombies 35:45 – Kyle Franko Interview

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes back Brian Dohn to the show for an extensive conversation about three Rutgers commitments and the start of training camp. Dorian Miller follows with a fun conversation in Chicago. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 7:00 – Recruiting Explosion with Brian Dohn 33:50 – Dorian Miller Returns! 48:45 – Rutgers Scoutcast Mailbag – Freshman Playing Time & Press Row Dining 53:33 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes welcomes star defenders Blessuan Austin and Sebastian Joseph. How will Austin handle his NFL speculation? What makes the charismatic, enigmatic Joseph tick? ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 6:10 – Blessuan Austin Interview 13:00 – Sebastian Joseph Interview 18:15 – Training Camp Week One Reactions 23:40 – Running Back Battle 28:50 – Recruiting Spotlight – Tre Avery 33:50 – Rutgers Scoutcast Mailbag – Ash vs. Schiano & Nerd Stuff 40:00 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes welcomes head coach Chris Ash to the show. Ash sits down with Hellman at Big Ten Media Day for a 1-on-1 Scoutcast spectacular.  ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 5:55 – Chris Ash Interview 13:30 – Training Camp Preview 21:50 – Recruiting Spotlight on Travon King 27:00 – Rutgers Scoutcast Mailbag – 2018 QB Battle & Media Day Madness 33:00 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes new Rutgers commit Adam Korsak. Korsak explains how his Australian upbringing led him to American football and the Rutgers Scarlet Knights. After that, we meet the newest member of the Scarlet Report staff and preview a big two weeks for the football fan base. ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 7:10 – Adam Korsak Interview 22:20 – Meet New Staff Member Brian Fonseca 28:00 – Big Ten Media Day Preview 33:45 – Scarlet Report Power 25 39:45 – Rutgers Scoutcast Mailbag – Corruption and Con Air 43:50 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes new Rutgers commit Paul Woods to the show for a commitment breakdown. Scout national recruiting analyst Brian Dohn joins us for a recruiting breakdown. AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 3:45 – Paul Woods Interview 12:05 – Paul Woods Commitment Breakdown 22:15 – Rutgers Scoutcast Mailbag – Media Day, Hoops and official visits. 31:00 – Close 33:30: Special Shoutout

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. in our latest episode, host Sam Hellman welcomes former Rutgers fan favorite Miles Shuler to the show. Shuler speaks candidly about his time at Rutgers, transfer to Northwestern and how both schools prepared him for a professional football career. After that, Scout national recruiting analyst Brian Dohn is back with his strong opinions and expert insight. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 3:20 – Miles Shuler Interview 19:15 – Scout Recruiting Spotlight – Coatesville CB Avery Young 26:40 – adidas Transition 28:30 – Facility Progress and Lack of Progress http://www.scout.com/college/rutgers/story/1409302-25-days-until-the-big-ten-facility-upgrades 39:15 – Rutgers Scoutcast Mailbag 44:25 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, former Rutgers quarerback Mike Bimonte guest hosts alongside Sam Hellman. Hear from Bimonte about everything Rutgers including the inside perspective on the biggest stories of the Kyle Flood era.  NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 – Open 3:58 – Mike Bimonte Interview         4:44 – Committing to Rutgers, Greg Schiano as a Recruiter         9:43 – The Art of the Holder         10:30 – Coaching Carousel         12:46 – Violations By Rutgers         15:30 – Savon Huggins         18:06 – Recruiting Saeed Blacknall         20:50 – Gary Nova and the Quarterback Battle         24:30 – Coaching at Delaware         30:42 – The Day Greg Schiano Left 39:00 – Rutgers Scoutcast Mailbag – Offensive Evolution and a Twitter Feud? 45:26 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we hear from incoming freshman wide receiver Everett Wormley of Burlington (N.J.) Township. Afterwards, Scout national recruiting analyst Brian Dohn is here with host Sam Hellman for an in-depth, honest breakdown of Chris Ash's first full Rutgers recruiting class. The good, the bad and the future -- we break it down in our longest episode to date. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 Open 1:55 – Adidas Deal 9:05 – CBS Discussion 11:25 – Everett Wormley Interview 21:45 – National Signing Day Reaction           23:00 – Rutgers Got its Quarterback           25:53 – Reaching in January?           31:30 – Relationships in New Jersey           35:40 – Chris Ash's First Year           42:03 – Who Outplays their Ranking?           52:35 – Final Thought (Not the Jerry Springer Kind) 53:24 – Rutgers Scoutcast Mailbag – Henry Baker and Recruiting Coverage 1:01:43 – Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we hear from Rutgers head coach Chris Ash, director of high school relations Rick Mantz and recruiting staff member Dan Spittal. All three have stories about the massive Rutgers presence in Super Bowl LI. After our interviews, host Sam Hellman hosts the final mailbag segment before National Signing Day. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 6:50 - Rutgers coach Chris Ash 10:05 - Rutgers Director of High School Relations Rick Mantz 18:40 - Dan Spittal of the Rutgers Recruiting Staff 26:45 - Rutgers Scoutcast Mailbag -- Recruiting Finish, Free Throws, New to Rutgers and the Royal Rumble

We hear that the concept of the family meal is history? Is that true and does it matter? In this episode of the Karma Sense Foodcast, we explore what science says about the shared family meal. Then we hear from Sam Hellman about his recollection of what family meals were like with the H family and how that affected him as he grew up. Finally, Sam and I do some improvisational cooking and share a meal. Eavesdrop on the way we do it and compare and contrast your own family relationship with mealtime. 01:00     Introduction 02:16     Rant - The Science Behind the Family Meal 06:15   Families Being Healthy and Well 07:28     Interview - Sam Hellman, Publisher of ScarletReport.com, Host of the Rutgers Scoutcast 31:16     Improvised Healthy Jalapeno Poppers 44:00     Wrap Up For complete show notes, go to http://www.daveyhwellness.com/nutrition/family-table/

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we hear from a pair of Rutgers assistant coaches -- Lester Erb and AJ Blazek. Then a fired-up Brian Dohn puts on his analyst hat for an in-depth Rutgers discussion with host Sam Hellman. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 5:30 - Rutgers RB Coach Lester Erb 9:45 - OL Coach AJ Blazek on Early Enrollment 14:25 - Rutgers Big Picture with Scout National Recruiting Analyst Brian Dohn 38:10 - Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we hear from new offensive coordinator Jerry Kill during his first week on the job. After the interview segment, Scout national recruiting analyst Brian Dohn joins host Sam Hellman to discuss coaching change at Rutgers, early signing period propsals and the state of the basketball program. Stay tuned for a fun cameo at the close. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 6:50 - Media Session with Jerry Kill 21:15 - Coaching Change Analysis 28:20 - Early Signing Period for Football? 33:05 - Rutgers Basketball Grinds through January 21:20 - Tom Izzo Cameo and Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we hang with starting quarterback Giovanni Rescigno for a chat about his new-found spotlight, music and Def Jam Vendetta. We also visit with wrestling coach Scott Goodale on the eve of "Battle at the Birthplace." After the interviews, host Sam Hellman breaks into an extended mailbag segment. Enjoy. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 5:40 - Interview with Giovanni Rescigno 11:25 - Interview with Scott Goodale 14:30 - Rutgers Extended  Mailbag          17:10 - Wide Receiver Depth            21:40 -- Assistant Coaches          24:00 - Roster Development          26:00 - Steve Pikiell solid start          28:00 -- Running Back recriting          29:45 - Vegetarian Thanksgiving (gross) 33:00 - Close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we spend some time with senior offensive lineman and team captain Chris Muller. Despite a down season for the team, Muller discusses his enjoyment of a final semester at Rutgers, as well as some off-topic shenanigans. After the interview, host Sam Hellman breaks into an extended mailbag segment. Enjoy. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 5:35 - Interview with Chris Muller 12:30 - Rutgers Extended  Mailbag          12:45 - C.J. Gettys          17:10 - 2006 Celebration           23:10 - Biggest surprise of the season          24:40 - Podcast plugs and close

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we jump into the wrestling conversation as the Battle at the Birthplace approaches. The Rutgers Scoutcast sits down with two of the program's top wrestlers in two-time All-American Anthony Ashnault and returning NCAA qualifier Nick Gravina. After our interviews, Sam Hellman and Brian Dohn reflect upon the 2006 Rutgers football season on the eve of kickoff against Indiana, where the program honors the team. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 11:05 - Anthony Ashnault Interview 19:45 - Nick Gravina Interview 25:15 - The 2006 Season

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we have double guests yet again. It starts with Sam Hellman's visit to Baltimore Calvert Hall and four-star Rutgers commit Tyshon Fogg. After we hear from  Fogg, take a trip down I-95 to Northwest Washington DC where we bring you the best of Rutgers basketball coach Steve Pikiell at Big Ten Media Day. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 7:15 - Interview with Tyshon Fogg 14:45 - The Best of Steve Pikiell 25:00 - Rutgers Mailbag - Basketball Size & Homecoming 33:00 - Close For Past Episodes and a Packed Interview Archive, Click Below.

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we break down the upcoming season and tomorrow's kickoff at Washington with special guest Chris Carlin. Scout national recruiting analyst Brian Dohn visits the Rutgers Scoutcast to preview and predict the first season under coach Chris Ash. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 7:30 - Chris Carlin Joins the Show         - 8:30 - Carlin's history with Rutgers         - 15:00 - Facilities         - 21:20 - Rutgers Football Season Discussion         - 33:30 - The Big Three  43:45 - Rutgers Mailbag - cornerback depth, quality control and keys to the game 54:30 - Brian Dohn and Sam Hellman give season predictions  

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, we welcome one half of your NJ.com Rutgers beat crew in Ryan Dunleavy. Dunleavy speaks with host Sam Hellman about his transition to a different news outlet, Big Ten Media Day, Chris Ash's media restrictions and training camp. NOW ON ITUNES AND STITCHER Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 6:46 - Check Out fanessentials.net and use our promo code "scarlet" at checkout for big savings! 8:20 - Ryan Dunleavy Interview 21:30 - Geo Baker Recruiting Spotlight 26:00 - The Ballad of Darius Stills 33:00 - Pat Hobbs Cameo 35:00 - Rutgers Mailbag -- Fan Attendance and  Fat Sandwiches 40:30 - Close    

It is our annual Rutgers Scarlet Knights preview, as Andy and Kevin talk all things RU football in the new Chris Ash era. Joining us to discuss things from an insiders perspective is Sam Hellman from ScarletReport on the Scout.com network.  Mention this podcast to @SamHellmanScout and you can get an extended free trial. 

  The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our latest episode, Scout director of recruiting Brandon Huffman offers his take on a massive week for Rutgers football in recruiting. With Rutgers at No. 17 in the Scout 2017 team rankings, national recruiting analyst Brian Dohn and publisher Sam Hellman discuss the newest wave of commitments and take your questions. Please rate, review and subscribe. To jump right into the action, a timesheet is available below for your convenience. 0:00 - Open 4:00 - Scout director of recruiting Brandon Huffman 18:00 - Chris Ash charity golf tournament 22:00 - Recruiting Surge 39:00 - Rutgers mailbag -- memorable opponents and pizza

The Rutgers Scoutcast is a weekly podcast for Rutgers fans of all varieties. In our 15th episode, host Sam Hellman welcomes guest host Tyler Donohue of Bleacher Report to discuss the news of the day, Johnathan Lewis at the Elite 11 (7:20), (11:45) Cedar Creek's rise in South Jersey and his time with the Rutgers football staff (19:30).  (33:45) National recruiting analyst Brian Dohn joins the show to discuss ranking and evaluating new Rutgers commit C.J. Onyechi. (39:00) In this week's Rutgers mailbag segment, Hellman discusses his expectations in 2016 for quarterback Zach Allen, who enrolled as a graduate transfer this week after three seasons with TCU  

Rutgers legend Eric LeGrand joined the Rutgers Scoutcast to promote and discuss his upcoming Walk to Believe Fundraiser. The Walk to Believe event raised money annual for the Christopher and Dana Reeve Foundation. With lofty goals in year five, LeGrand discussed his personal connection to the charity and goals of beceoming a voice for spinal cord research. LeGrand also has some fun with host Sam Hellman about their early days at Rutgers, Game of Thrones and the best meal on campus.

Rutgers wrestling made history in 2016 with the biggest NCAA tournament showing for the program. With 10 NCAA qualifiers and two All-Americans, head coach Scott Goodale sat down with Sam Hellman in the Barn. Goodale discusses his journey to Rutgers that began in 2007 after a career with Jackson (N.J.) Memorial. Goodale previews the NCAA tournament and hits on other topics including his favorite Rutgers memories and a relationship wtih UFC star Frankie Edgar.

Football Talk & Indiana Preview w/ Guests from HoosierHuddle.com & Sam Hellman of ScarletReport.com. 9:30 PM Wednesday Special. Call-ins wanted at top of 10 o'clock hour at (914) 338-1694